---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-021525"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T03:46:06.532925+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acumen updates INTERCEPT-AD trial enrollment, dose reduction for Cohort 7

## Summary
- Expects enrollment completion Q1 2023, topline data Q3 2023.
- 52 subjects randomized and dosed in Cohorts 1-6 as of Jan 31, 2023.
- Submitted protocol amendment Jan 30, 2023: Cohort 7 reduced to 25 mg/kg every 2 weeks from 60 mg/kg.
- Two asymptomatic ARIA-E cases: one in Cohort 4 (single 60 mg/kg), one in Cohort 5 (third 10 mg/kg).
- Dose reduction based on blinded PK/PD data; 60 mg/kg every 2 weeks deemed unnecessary for target engagement.

## SEC filing metadata
- accession: 0001193125-23-021525
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312523021525/0001193125-23-021525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312523021525/d453609d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-021525
- JSON: https://secwatch.observer/filing/0001193125-23-021525.json
- Plain text: https://secwatch.observer/filing/0001193125-23-021525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.